Trailblazing the path to transcription factors by intervening at a previously hidden region we have identified as the ‘switch site.’



To date, the collective research on transcription factors has been elusive to drug discovery. However, Flare Therapeutics has now reached a moment of light – with the prospect of forever changing the trajectory of how we treat disease.



Flare’s pipeline is Initially focused on precision oncology.

Our small molecules are designed to regain transcriptional control that is hijacked by cancer.




Intensity, empathy, determination, and brilliance. The Flare Therapeutics team is a living, growing, thriving organization of talented people and bright minds. We are always looking for new sparks to flame our collective fire. Learn more about our culture and join us!

  Join Us

Flare Therapeutics Presents Comprehensive Real-World Data in Advanced and Metastatic Urothelial Cancer in Support of Therapeutic Targeting of PPARG at 2022 EORTC-NCI-AACR Symposium
Molecular Real-World Data (RWD) from 3,000+ individuals with advanced and metastatic urothelial cancer highlight Peroxisome Proliferator-Activated Receptor Gamma (PPARG) as a lineage defining transcription factor is foundational to Flare’s precision oncology approach

  Read full story


This links to an external website.